ME Therapeutics

Company snapshot

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor c

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 27 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ME Therapeutics. Not investment advice.

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  Zentalis Pharmaceuticals

  TA overlap score 32.8

• Peer + 0 momentum

  ALX ONCOLOGY HOLDINGS

  TA overlap score 32.6

• Peer + 0 momentum

  Syndax Pharmaceuticals

  TA overlap score 29.4

• Peer + 0 momentum

  RIGEL PHARMACEUTICALS

  TA overlap score 27.2

• Peer + 0 momentum

  NORTHWEST BIOTHERAPEUTICS

  TA overlap score 26.6

• Peer + 0 momentum

  ADC Therapeutics

  TA overlap score 26

• Peer + 0 momentum

  CASI Pharmaceuticals

  TA overlap score 24.4

• Peer + 0 momentum

  Prelude Therapeutics

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for ME Therapeutics.

1. Jun 8, 2026 Clinical update

   Low dose FRα vaccine — Phase 2

2. Jun 8, 2026 Clinical update

   FRα peptide plus Adjuvant (GM-CSF) — Phase 2

3. Jun 8, 2026 Clinical update

   Urinary EDC metabolite testing — Unknown

4. Jun 8, 2026 Clinical update

   Urinary EDC metabolite testing — Unknown

5. Jun 8, 2026 Clinical update

   blood sampling — Unknown

View all clinical trial activity →

• What is ME Therapeutics?

  ME Therapeutics is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker MRKR. Primary therapeutic focus areas include Colorectal Cancer Screening, Screening for Colon Cancer, Platinum Sensitive Ovarian Cancer, HER2-positive Breast Cancer, Breast Ca

• Is ME Therapeutics publicly traded?

  Yes. ME Therapeutics is listed with ticker MRKR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ME Therapeutics develop or market?

  We link 10 drug profile(s) where ME Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/marker-therapeutics#company-drugs.

• What are the latest developments for ME Therapeutics?

  In the last 12 months our linked public records show 13 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ME Therapeutics focus on?

  ME Therapeutics focuses on Colorectal Cancer Screening, Screening for Colon Cancer, Platinum Sensitive Ovarian Cancer based on our analysis of their pipeline programs and drug development activities.